Lipid Nanoparticles (LNP) Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Solid Lipid Nanoparticles (SLN), Nanostructured Lipid Carriers (NLC), and Others), By Product (mRNA, siRNA, Plasmid DNA, and Others), By Application (Vaccines & Drugs, and Scientific Research) and Region Forecast 2019-2030

Lipid Nanoparticles (LNP) Market size was valued at US$  906.6 million in 2023 and is poised to grow at a significant CAGR of 6.6% from 2024-2030. Nanoparticles have received interest recently because of their potential role in efficient medication delivery. LNPs are now widely recognized in the pharmaceutical and biotechnology sectors as a cutting-edge, commercially successful delivery system enabling the unheard-of commercialization of gene treatments. As a result, LNPs have ushered in a new era of medicine that allows for the effective treatment or cure of genetic illnesses and the production of vaccines within the body rather than through the purification of non-infectious viruses.

Lipid nanoparticles offer several important characteristics over widely used lipid-based nucleic acid delivery systems such as:

• High nucleic acid encapsulation efficiency and potent transfection
• Improved penetration into tissues to deliver therapeutics
• Low cytotoxicity and immunogenicity
• Targeted Therapy
• Escape from the endosomes

For the creation of therapeutic products for protein replacement therapy, preventive or curative vaccinations, and gene editing, LNP-based formulations provide significant prospects. LNP-based formulations are increasingly being considered for use across a variety of other application areas, including anticancer agents and antibiotics, peptide and protein-based synthetic vaccines, ligand targeted formulations, and imaging contrast agents, in addition to RNA, DNA, and siRNA-based therapeutics. LNPs are anticipated to facilitate the creation of ever more sophisticated nanomedicines during the next ten years. Examples include the design of synthetic vaccines, immunotherapies, and drug combination products when LNP-based formulations are necessary to guarantee the co-presentation of various components into the target cell. Personalized or custom formulations that can enable results like the insertion of tumor-associated neoantigens into mRNA vaccines are another opportunity that can be achieved by combining LNPs with tissue sequencing and other valuable technologies.

Key Developments:

• In February 2021, Merck KGaA announced the extension of its strategic partnership with BioNTech to accelerate the supply of urgently needed lipids and increase the quantities to be delivered in 2021. The lipids were used for the production of the Pfizer-BioNTech Covid-19 vaccine.
• On 6th February 2023, Croda (Avanti) offering lipid nanoparticles to the cosmetics and agrobusiness customers. To strengthen its presence in the cosmetics and pharmaceuticals, company has acquired the  Solus Biotech, leader in the biotechnology-derived active ingredients for beauty care and pharmaceuticals. Solus Biotech acquisition provides Croda, to access their R&D hub in the Asia Pacific region and also it brings portfolio of phospholipids.
• On 6th July 2020, Croda’s acquired Avanti Polar Lipids to strengthen its Nucleic Acid Delivery platform, which is a technology area that focuses on lipid-based drug delivery systems that carry nucleic acid material.
• On 9th September 2022, WuXi STA opened a new sterile lipid nanoparticle formulation facility at its Wuxi city campus owing to increase in demand for the complex injectables and lipid nanoparticles. This facility will help the company to enhance global CDMO services for its customers. This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform, offering significant advantages in drug-loading, liposome particle size control, and encapsulation efficiency.  In addition, the modular design provides greater processing flexibility, enabling this platform to serve a wide range of manufacturing scales from 10-50 L per batch. manufacturing capacity of ingredients for lipid systems used in novel therapeutic drugs, such as mRNA vaccines.  In line with the company’s strategy to ‘Empower Biologics Delivery,’ Croda will also invest up to $58 million, bringing the total project investment to up to $133 million.
• On 9th August 2023, AstraZeneca entered into an agreement with CanSino Biologics, will use its mRNA manufacturing platform to support AZ on the R&D of certain vaccines. In May 2020, CanSino Biologics signed a deal with the Precision NanoSystems to develop an mRNA lipid nanoparticle vaccine.